While neither of our patients received anti-IL-1 therapy during pregnancy, this may be a reasonably safe option for patients needing more than glucocorticoids to control AoSD/MAS during pregnancy, or in cases where glucocorticoids must be minimized, such as in gestational diabetes. This evidence concerns the gene IL1B and gestational diabetes.